David Bruce Hedden

Title: The Innovative Contributions of David Bruce Hedden

Introduction

David Bruce Hedden, an accomplished inventor based in Ann Arbor, Michigan, has made significant strides in the field of pharmaceuticals. With a total of 12 patents to his name, he has been instrumental in developing innovative solutions for treating various medical conditions, particularly Parkinson's disease. His pioneering work is recognized for its impact on enhancing patient care and treatment efficacy.

Latest Patents

Among his most recent innovations are two patents focusing on sublingual formulations of apomorphine. The first patent discloses sublingual formulations that consist of films or strips containing a combination of apomorphine particles and pH neutralizing agents. This unique delivery method aims to improve the treatment of Parkinson's disease by ensuring effective absorption. The second patent outlines methods for preparing a mucoadhesive film that incorporates apomorphine particles. This involves combining a film-forming polymer with the apomorphine particles and a solvent, creating an intermediate film that is subsequently treated with a pH neutralizing agent for optimized performance.

Career Highlights

David has contributed to the pharmaceutical industry through key positions at notable companies. He has worked at Sunovion Pharmaceuticals, Inc., where he was involved in developing advanced formulations and therapeutic solutions. Additionally, his experience at Jenike & Johanson, Inc. has equipped him with skills in process design and material handling, further enriching his expertise in pharmaceutical innovations.

Collaborations

Throughout his career, David has collaborated with distinguished colleagues, including Anthony John Giovinazzo and Nathan Bryson. Together, they have worked on various projects that have contributed to advancements in medical treatments and formulations, showcasing the collaborative spirit of innovation in the research community.

Conclusion

David Bruce Hedden's contributions to the field of pharmaceuticals exemplify the essence of innovation through practical solutions for complex medical challenges. His latest patents in sublingual apomorphine formulations represent a push towards better treatment options for patients suffering from Parkinson's disease. As he continues to work at the intersection of research and application, his legacy of innovation promises to inspire future advancements in the healthcare industry.